By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Kite Pharma, Inc. 

2225 Colorado Avenue

Santa Monica  California  90404  U.S.A.
Phone: 301-824-9999 Fax: n/a


Company News
Kite Pharma (KITE) Announces Exclusive License With NIH For Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) Product Candidate To Treat B-Cell Malignancies 7/28/2016 11:17:00 AM
Kite Pharma (KITE) Licenses Enabling Technology For The Development Of Off-the-Shelf Allogeneic T-Cell Therapies 7/26/2016 10:35:02 AM
BioLife Solutions, Inc. (BLFS.OB) Executes 10 Year Supply Agreement With Kite Pharma (KITE) For CryoStor Use In CAR T Cell Therapies 7/11/2016 6:50:39 AM
Kite Pharma (KITE) Completes Enrollment Of All Patients With Diffuse Large B-Cell Lymphoma (DLBCL) In Pivotal Multi-Center Phase 2 Study Of KTE-C19 (ZUMA-1) 7/8/2016 11:17:22 AM
Kite Pharma (KITE) and Juno (JUNO)'s R&D Strategy to Reshape Cancer Treatment 6/21/2016 7:25:19 AM
Kite Pharma (KITE) Opens Up New T-Cell Therapy Manufacturing Plant in California 6/21/2016 6:26:57 AM
Kite Pharma (KITE) Expands Development Of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers In Partnership With The NCI 6/20/2016 10:45:28 AM
Kite Pharma (KITE) To Highlight Key Data From CAR T-Cell Therapy Pipeline In Oral Presentations At The 2016 European Hematology Association Annual Congress 6/8/2016 8:19:05 AM
ASCO2016: Kite Pharma (KITE)/NCI Anti-CD19 CAR T-Cell Therapy Demonstrates Durable Complete Remissions In Advanced Non-Hodgkin Lymphoma 6/6/2016 9:23:17 AM
ASCO2016: Kite Pharma (KITE) Presents Ongoing Complete Responses At 9 Months In Phase I Of ZUMA-1 In Patients With Chemorefractory Non-Hodgkin Lymphoma 6/6/2016 9:21:04 AM